Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 06 04:00PM ET
3.86
Dollar change
-0.09
Percentage change
-2.28
%
Index- P/E- EPS (ttm)-7.81 Insider Own11.73% Shs Outstand8.47M Perf Week-12.07%
Market Cap31.94M Forward P/E- EPS next Y-4.38 Insider Trans0.00% Shs Float7.47M Perf Month-8.10%
Income-45.48M PEG- EPS next Q-1.34 Inst Own23.79% Short Float2.18% Perf Quarter-21.86%
Sales10.26M P/S3.11 EPS this Y22.88% Inst Trans-5.40% Short Ratio3.17 Perf Half Y-56.33%
Book/sh-1.45 P/B- EPS next Y36.61% ROA-68.68% Short Interest0.16M Perf Year-69.12%
Cash/sh2.52 P/C1.53 EPS next 5Y- ROE-436.16% 52W Range3.51 - 17.49 Perf YTD-69.73%
Dividend Est.- P/FCF- EPS past 5Y14.56% ROI-222.53% 52W High-77.93% Beta3.36
Dividend TTM- Quick Ratio1.22 Sales past 5Y-0.68% Gross Margin92.79% 52W Low9.97% ATR (14)0.37
Dividend Ex-Date- Current Ratio1.22 EPS Y/Y TTM16.44% Oper. Margin-465.42% RSI (14)38.67 Volatility8.53% 9.62%
Employees49 Debt/Eq- Sales Y/Y TTM0.44% Profit Margin-443.35% Recom1.40 Target Price21.00
Option/ShortNo / Yes LT Debt/Eq- EPS Q/Q20.22% Payout- Rel Volume1.81 Prev Close3.95
Sales Surprise29.26% EPS Surprise7.10% Sales Q/Q3.46% EarningsNov 14 BMO Avg Volume51.23K Price3.86
SMA20-5.22% SMA50-16.39% SMA200-52.34% Trades Volume92,881 Change-2.28%
Date Action Analyst Rating Change Price Target Change
Nov-17-23Initiated Truist Buy $26
Apr-04-22Downgrade Raymond James Outperform → Mkt Perform
Oct-13-21Initiated Raymond James Outperform $15
Mar-25-21Initiated B. Riley Securities Buy $19
Jul-29-20Initiated Laidlaw Buy $5
Jul-17-20Initiated Cantor Fitzgerald Overweight $4
Oct-24-17Initiated Guggenheim Buy $7
Mar-02-16Initiated Sun Trust Rbsn Humphrey Buy $3
Nov-09-15Reiterated ROTH Capital Buy $6 → $5
Aug-11-15Initiated FBR Capital Outperform $6
Nov-15-24 02:37AM
02:07AM
Nov-14-24 09:10AM
08:09AM
08:00AM
07:31AM Loading…
Nov-13-24 07:31AM
Nov-07-24 08:00AM
Nov-02-24 11:20AM
Oct-29-24 06:04AM
Oct-09-24 03:42PM
Sep-23-24 08:30AM
Sep-17-24 07:30AM
Sep-04-24 08:00AM
Aug-01-24 09:10AM
08:07AM
08:00AM Loading…
08:00AM
Jul-25-24 08:00AM
Jul-10-24 07:30AM
Jul-09-24 12:00PM
Jul-08-24 07:30AM
May-14-24 04:00PM
May-10-24 08:00AM
May-08-24 11:39AM
May-07-24 12:53PM
08:08AM
08:00AM
Apr-30-24 08:00AM
Apr-05-24 08:43AM
07:30AM
Apr-04-24 07:30AM
10:10AM Loading…
Feb-09-24 10:10AM
Feb-08-24 08:11AM
08:00AM
Feb-01-24 08:00AM
Jan-05-24 08:00AM
Dec-12-23 08:00AM
Dec-11-23 08:00AM
Dec-06-23 08:00AM
Dec-05-23 08:00AM
Nov-03-23 10:26AM
06:03AM
Nov-02-23 08:19AM
08:00AM
Oct-30-23 10:00AM
Oct-26-23 08:30AM
Oct-06-23 08:56AM
Sep-22-23 03:15AM
Sep-12-23 08:00AM
Sep-06-23 08:13AM
Aug-05-23 05:57AM
Aug-03-23 05:45PM
04:43PM
04:01PM
Jul-27-23 06:25PM
Jul-06-23 08:01AM
08:00AM
Jun-30-23 06:50AM
Jun-06-23 06:54AM
May-15-23 11:33AM
May-05-23 07:30AM
May-04-23 05:45PM
04:26PM
04:01PM
Apr-27-23 04:01PM
Apr-17-23 08:12AM
Apr-05-23 08:13PM
Apr-03-23 08:00AM
Mar-14-23 11:02AM
Mar-13-23 10:21PM
09:15AM
08:00AM
Mar-08-23 07:09PM
Mar-02-23 04:01PM
Jan-20-23 10:09AM
Dec-12-22 10:00AM
Dec-05-22 11:08PM
Nov-12-22 07:43AM
Nov-10-22 02:30PM
Nov-09-22 05:45PM
04:01PM
08:27AM
Nov-07-22 04:01PM
Nov-02-22 04:00PM
Oct-07-22 04:01PM
Oct-03-22 04:01PM
Sep-19-22 09:16PM
Sep-07-22 08:00AM
Aug-31-22 12:53PM
Aug-30-22 08:52AM
08:00AM
Aug-19-22 12:25PM
Aug-18-22 08:49AM
08:00AM
Aug-13-22 10:05AM
Aug-05-22 03:30AM
Aug-04-22 06:25PM
04:01PM
Jul-29-22 04:00PM
Jul-28-22 04:00PM
Jul-08-22 07:56AM
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.